HUTCHMED's Sovleplenib Wins FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

• HUTCHMED secured FDA orphan drug designation for sovleplenib to treat primary immune thrombocytopenia, an autoimmune disorder that increases bleeding risk.
• The designation offers seven years of US market exclusivity upon approval, alongside development incentives.
• Chinese regulators are reviewing sovleplenib applications for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia.
• Positive results already obtained from China's pivotal ESLIM-01 and ESLIM-02 trials support the respective applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610282000PRIMZONEFULLFEED9855451) on October 29, 2026, and is solely responsible for the information contained therein.